To prove that the changes in Bcl-2 expression observed in BC cells with various contents of GalCer directly affects their sensitivity to anti-cancer drugs, MDA.C cells with high levels of GalCer and high Bcl-2 expression were treated with ABT-199, which is a selective Bcl-2 inhibitor [25], and subsequently incubated with DOX. This evidence concerns the gene BCL2 and cancer.